Tamtam Try Tamtam free
Fresenius Medical Care logo

Fresenius Medical Care account plan

Renal disease treatment services

At a glance

Fresenius Medical Care runs 3,601 dialysis centers and makes dialysis products for 140+ countries, with €19,628 M of 2025 revenue.

Fresenius Medical Care (FME), headquartered in Bad Homburg v. d. Höhe, Germany, is a vertically integrated kidney care group: it runs the world's largest dialysis clinic network (3,601 clinics in more than 30 countries treating 291,902 patients at end-2025) and makes dialysis machines, dialyzers and consumables sold in more than 140 countries. About 70% of its patients are treated in the U.S., where it treats about 37% of dialysis patients. In 2025 revenue was €19,628 M (+5% at constant currency), operating income excluding special items €2,212 M (11.3% margin) and net income attributable to shareholders €978 M. It employed 109,698 people at end-2025 and 107,226 at June 30, 2026.

Business units

Strategic priorities

FME Reignite strategy to 2030
Strengthen core operations, drive profitable growth and innovation, and develop the culture; aspiration of a mid-teens operating income margin by 2030 and operating income CAGR of 3-7% from 2025 to 2028.
High-volume hemodiafiltration in the U.S.
Replace about 20% of its own U.S. machines with the 5008X in 2026, training more than 7,200 nurses and technicians and moving around 36,000 patients across 28 states, with the goal of 100% by 2030.
FME25+ savings
€804 M of sustainable savings by end-2025, €920 M by mid-2026, and a target of €1.2 BN by end-2027 across supply chain, procurement, clinic footprint and Global Business Services.
Restore U.S. referral capture
U.S. same market treatment growth was -0.9% in Q2 2026; organizational changes in business development aim to improve referral conversion, with recovery seen mostly in 2027 and an aspiration to return to +2% plus.
Capital returns and leverage
Dividend payout of 30-40%, a new ~€1 BN buyback launched in May 2026, capex of about €0.8-1.0 BN a year and a net leverage target of 2.5-3.0x.

Latest results

In Q2 2026 revenue was €4,861 M (+4% at constant currency, 5% organic) and operating income excluding special items €569 M, up 23% at constant currency; Care Delivery operating income rose 33% at constant currency on TDAPA reimbursement, rate increases and FME25+ savings. For H1 2026 revenue was €9,473 M and net income attributable to shareholders €336 M (-11%). U.S. volumes fell, which management called "our own clear operational miss" in referral capture. The 2026 outlook was confirmed in October: revenue broadly flat and operating income within a +/- mid-single-digit range of €2,212 M, with negative H2 earnings growth as TDAPA turns into a headwind.

Investments and deals

5008X fleet rollout
By late July 2026, 227 clinics in 23 states were converted (10% of the machine base) and about 5,000 nurses and technicians trained; 2026 capex is expected at about €0.8-1.0 BN.
Share buybacks
The first €1 BN program was completed in April 2026 with 24,848,819 shares; a new ~€1 BN program runs to May 27, 2027, with 9.1m shares bought for €357.1m by September 30, 2026.
Legacy portfolio optimization
Exits from clinic operations in Brazil, Malaysia and Kazakhstan, sale of select Spectra Laboratories assets, and in China discontinuation of the 4008A platform with about €110 M of one-time costs.
ERP and production sites
Move to SAP S/4HANA (around €80 M of 2026 corporate costs) and purchase of the Schweinfurt and St. Wendel production sites for €181 M in 2025.

Challenges and risks

U.S. volume capture
U.S. same market treatment growth is expected around -0.9% for 2026 after an organizational redesign and around 100 clinic exits in H1 disrupted referrals.
Reimbursement headwinds
TDAPA phosphate binder add-ons end in 2027, ACA subsidy expiry costs €50 M in 2026, and the proposed 2027 ESRD bundle rises only 1.1%.
China volume-based procurement
Volume-based procurement and stricter tenders in China weigh on Care Enablement, with an impact around €50 M for 2026.
Quality, cyber and supply costs
FDA warning letters led to a quality management enhancement program; a cybersecurity incident occurred in late September 2026; the Middle East conflict raised procurement risk to medium.
Leadership change
Shervin J. Korangy succeeded Helen Giza as CEO on October 12, 2026, as the Supervisory Board judged the transformation "has largely achieved its objectives".

What leadership says

“We are not seeing a market issue. We are seeing a volume capture issue in terms of getting the patients that we see into our clinics.”

Helen Giza, then CEO · Q2 2026 earnings call, August 4, 2026

“2025 was a milestone year for Fresenius's Medical Care. We delivered an outstanding step up in profitability”

Helen Giza, then CEO · Q4 and full year 2025 earnings call, February 24, 2026

“We knew 2026 will be a transition year, which does not change our aspiration to achieve industry-leading growth and margins.”

Helen Giza, then CEO · Q4 and full year 2025 earnings call, February 24, 2026

Where a supplier can help

Clinical training and change management for HDF
Converting thousands of machines and training thousands of clinicians in the 5008X rollout creates demand for training, field service and logistics support tied to the HDF priority.
Referral management and patient intake
The U.S. volume shortfall is a referral conversion issue; referral tracking, CRM, insurance verification and patient onboarding tools address it directly.
Procurement and supply chain savings
FME25+ targets supply chain, procurement and Global Business Services savings, and Middle East inflation raised procurement risk; sourcing, logistics and spend analytics offers fit.
Quality and cybersecurity
FDA warning letters and a September 2026 cyber incident point to needs in quality management systems, regulatory compliance and security for connected devices.
ERP migration
The SAP S/4HANA move carries tens of millions of euros of 2026 costs; integration, data migration and implementation partners fit this investment.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Fresenius Medical Care?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Fresenius Medical Care

What does Fresenius Medical Care do?

It provides dialysis care through 3,601 clinics in more than 30 countries and makes dialysis machines, dialyzers and consumables, and runs a U.S. value-based kidney care business, Interwell Health.

What was Fresenius Medical Care's revenue in 2025?

€19,628 M, up 5% at constant currency, with operating income excluding special items of €2,212 M.

How many employees does Fresenius Medical Care have?

109,698 at end-2025 and 107,226 at June 30, 2026, with 54% in the U.S. at end-2025

Who is the CEO of Fresenius Medical Care?

Shervin J. Korangy, former CEO of BVI Medical, became CEO and Chairman of the Management Board on October 12, 2026, succeeding Helen Giza; Martin Fischer is CFO.

What is Fresenius Medical Care's strategy?

FME Reignite aims for a mid-teens operating margin by 2030, driven by the U.S. high-volume hemodiafiltration rollout, FME25+ savings of €1.2 BN by end-2027 and profitable growth.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)